| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99444 |
|
14,396 |
3,565 |
$822K |
| 99423 |
|
6,983 |
1,716 |
$396K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
18,560 |
13,660 |
$302K |
| 95165 |
Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials |
1,415 |
608 |
$90K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
1,046 |
1,001 |
$52K |
| 95004 |
Percutaneous tests with allergenic extracts, immediate type reaction |
274 |
267 |
$28K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
1,411 |
1,278 |
$26K |
| 99000 |
|
3,672 |
3,340 |
$22K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
2,760 |
2,206 |
$19K |
| 99490 |
Ccm add 20min |
5,726 |
5,724 |
$19K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
409 |
400 |
$18K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
215 |
202 |
$16K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,566 |
1,487 |
$16K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
432 |
409 |
$12K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
858 |
493 |
$7K |
| 71046 |
Radiologic examination, chest; 2 views |
929 |
862 |
$6K |
| 95923 |
|
551 |
530 |
$6K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
3,433 |
3,273 |
$5K |
| 84443 |
Thyroid stimulating hormone (TSH) |
1,370 |
1,312 |
$5K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
2,195 |
1,344 |
$5K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
2,374 |
2,298 |
$4K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
533 |
281 |
$4K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
54 |
52 |
$4K |
| 82044 |
|
3,005 |
2,886 |
$4K |
| 93000 |
|
1,039 |
1,001 |
$4K |
| 87081 |
|
781 |
732 |
$3K |
| 84439 |
|
1,392 |
1,335 |
$3K |
| 99091 |
|
199 |
198 |
$3K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
55 |
49 |
$3K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
790 |
774 |
$2K |
| 95117 |
|
816 |
285 |
$2K |
| 82948 |
|
2,145 |
1,719 |
$2K |
| 82570 |
|
2,284 |
2,207 |
$2K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
56 |
54 |
$2K |
| 81003 |
|
3,336 |
3,131 |
$2K |
| 90756 |
|
370 |
365 |
$2K |
| 90674 |
|
293 |
287 |
$1K |
| 95250 |
|
178 |
161 |
$1K |
| 95943 |
|
144 |
141 |
$1K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
171 |
148 |
$1K |
| 95921 |
|
178 |
176 |
$1K |
| 82947 |
|
4,335 |
3,216 |
$1K |
| 0011A |
|
145 |
144 |
$1K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
31 |
26 |
$905.78 |
| 99497 |
|
522 |
491 |
$882.64 |
| 0012A |
|
129 |
129 |
$801.20 |
| 99051 |
|
293 |
262 |
$721.12 |
| 0013A |
|
144 |
143 |
$680.00 |
| 99457 |
|
268 |
267 |
$677.89 |
| 0001A |
|
24 |
24 |
$600.00 |
| 80048 |
Basic metabolic panel (calcium, ionized) |
1,834 |
1,786 |
$537.20 |
| 93922 |
|
280 |
279 |
$485.80 |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
20 |
20 |
$442.12 |
| 0002A |
|
12 |
12 |
$440.00 |
| 95251 |
|
165 |
157 |
$318.25 |
| 83721 |
|
1,608 |
1,591 |
$297.80 |
| 99496 |
|
16 |
14 |
$249.54 |
| 80076 |
|
1,712 |
1,686 |
$226.43 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
287 |
210 |
$221.31 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
563 |
480 |
$168.72 |
| 80061 |
Lipid panel |
1,607 |
1,587 |
$166.60 |
| 96160 |
|
131 |
106 |
$129.03 |
| 82607 |
|
113 |
103 |
$126.70 |
| G0328 |
Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous |
58 |
57 |
$122.62 |
| 82565 |
|
1,573 |
1,552 |
$121.59 |
| 90461 |
|
17 |
13 |
$78.86 |
| 80053 |
Comprehensive metabolic panel |
24 |
24 |
$69.20 |
| 96132 |
|
13 |
13 |
$51.54 |
| 93925 |
|
12 |
12 |
$43.80 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
457 |
385 |
$35.47 |
| 92540 |
|
13 |
13 |
$30.43 |
| J3420 |
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg |
226 |
194 |
$23.40 |
| 11719 |
|
14 |
12 |
$21.70 |
| 92546 |
|
13 |
13 |
$18.20 |
| 95930 |
|
14 |
13 |
$17.16 |
| 92547 |
|
13 |
13 |
$2.21 |
| 90686 |
|
119 |
115 |
$0.14 |
| 91301 |
|
191 |
189 |
$0.08 |
| 1100F |
|
280 |
275 |
$0.00 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
4,499 |
3,624 |
$0.00 |
| G8753 |
Most recent systolic blood pressure >= 140 mmhg |
188 |
167 |
$0.00 |
| G8783 |
Normal blood pressure reading documented, follow-up not required |
115 |
113 |
$0.00 |
| G8752 |
Most recent systolic blood pressure < 140 mmhg |
2,954 |
2,516 |
$0.00 |
| G8598 |
Aspirin or another antiplatelet therapy used |
598 |
547 |
$0.00 |
| G8482 |
Influenza immunization administered or previously received |
972 |
866 |
$0.00 |
| 4040F |
|
822 |
745 |
$0.00 |
| G8417 |
Bmi is documented above normal parameters and a follow-up plan is documented |
1,922 |
1,639 |
$0.00 |
| 1124F |
|
482 |
451 |
$0.00 |
| 3288F |
|
492 |
479 |
$0.00 |
| G0444 |
Annual depression screening, 5 to 15 minutes |
455 |
428 |
$0.00 |
| G8431 |
Screening for depression is documented as being positive and a follow-up plan is documented |
87 |
79 |
$0.00 |
| G9744 |
Patient not eligible due to active diagnosis of hypertension |
358 |
303 |
$0.00 |
| 2022F |
|
82 |
78 |
$0.00 |
| 1090F |
|
929 |
837 |
$0.00 |
| G0446 |
Annual, face-to-face intensive behavioral therapy for cardiovascular disease, individual, 15 minutes |
43 |
40 |
$0.00 |
| 3725F |
|
29 |
29 |
$0.00 |
| 99401 |
|
56 |
52 |
$0.00 |
| 3045F |
|
38 |
34 |
$0.00 |
| 95957 |
|
14 |
13 |
$0.00 |
| 0518F |
|
39 |
37 |
$0.00 |
| Q2037 |
Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin) |
52 |
52 |
$0.00 |
| 96138 |
|
13 |
13 |
$0.00 |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
17 |
14 |
$0.00 |
| G8730 |
Pain assessment documented as positive using a standardized tool and a follow-up plan is documented |
16 |
16 |
$0.00 |
| 3078F |
|
16 |
15 |
$0.00 |
| 90734 |
|
35 |
35 |
$0.00 |
| 92585 |
|
14 |
13 |
$0.00 |
| G0246 |
Follow-up physician evaluation and management of a diabetic patient with diabetic sensory neuropathy resulting in a loss of protective sensation (lops) to include at least the following: (1) a patient history, (2) a physical examination that includes: (a) visual inspection of the forefoot, hindfoot and toe web spaces, (b) evaluation of protective sensation, (c) evaluation of foot structure and biomechanics, (d) evaluation of vascular status and skin integrity, and (e) evaluation and recommendation of footwear, and (3) patient education |
14 |
14 |
$0.00 |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
21 |
16 |
$0.00 |
| 95816 |
|
14 |
13 |
$0.00 |
| G0442 |
Annual alcohol misuse screening, 5 to 15 minutes |
424 |
393 |
$0.00 |
| G8473 |
Angiotensin converting enzyme (ace) inhibitor or angiotensin receptor blocker (arb) therapy prescribed |
285 |
277 |
$0.00 |
| 36415 |
Collection of venous blood by venipuncture |
6,360 |
5,433 |
$0.00 |
| G8754 |
Most recent diastolic blood pressure < 90 mmhg |
3,361 |
2,818 |
$0.00 |
| 1170F |
|
554 |
528 |
$0.00 |
| G8420 |
Bmi is documented within normal parameters and no follow-up plan is required |
1,832 |
1,563 |
$0.00 |
| 4010F |
|
22 |
22 |
$0.00 |
| G8950 |
Elevated or hypertensive blood pressure reading documented, and the indicated follow-up is documented |
1,278 |
1,097 |
$0.00 |
| G0439 |
Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit |
407 |
401 |
$0.00 |
| 1111F |
|
93 |
85 |
$0.00 |
| 93040 |
|
13 |
13 |
$0.00 |
| 1036F |
|
481 |
474 |
$0.00 |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
253 |
251 |
$0.00 |
| 3017F |
|
122 |
113 |
$0.00 |
| 3044F |
|
669 |
604 |
$0.00 |
| G8450 |
Beta-blocker therapy prescribed |
108 |
98 |
$0.00 |
| G9664 |
Patients who are currently statin therapy users or received an order (prescription) for statin therapy |
411 |
390 |
$0.00 |
| G0009 |
Administration of pneumococcal vaccine |
42 |
42 |
$0.00 |
| G8734 |
Elder maltreatment screen documented as negative, follow-up is not required |
31 |
31 |
$0.00 |
| G0008 |
Administration of influenza virus vaccine |
538 |
477 |
$0.00 |
| 90620 |
|
35 |
35 |
$0.00 |
| G9903 |
Patient screened for tobacco use and identified as a tobacco non-user |
28 |
28 |
$0.00 |
| 1101F |
|
100 |
100 |
$0.00 |
| 3074F |
|
13 |
12 |
$0.00 |
| G8418 |
Bmi is documented below normal parameters and a follow-up plan is documented |
20 |
17 |
$0.00 |
| 90651 |
|
29 |
29 |
$0.00 |
| G8732 |
No documentation of pain assessment, reason not given |
14 |
14 |
$0.00 |